Drospirenone: a novel progestin

  title={Drospirenone: a novel progestin},
  author={Andrea Rapkin and Sharon A. Winer},
  journal={Expert Opinion on Pharmacotherapy},
  pages={989 - 999}
  • A. RapkinS. Winer
  • Published 1 May 2007
  • Medicine, Biology
  • Expert Opinion on Pharmacotherapy
Drospirenone is a novel progestin available in combined oral contraceptives and menopausal hormonal therapy. Similar to its parent compound spirolactone, an analog of spironolactone, drospirenone has antimineralocorticoid and antiandrogenic activity. Combined with ethinyl estradiol in oral contraceptive formulations, drospirenone-containing contraceptives have similar efficacy and safety profiles to other low-dose oral contraceptives, but seem to offer improved tolerability with regard to… 

Expert opinion on a flexible extended regimen of drospirenone/ethinyl estradiol contraceptive

Flexible extended dosing of a contraceptive containing drospirenone (DRSP) and ethinyl estradiol (EE) has similar pharmacokinetics and contraceptive efficacy of both conventional and fixed extended regimens, however, it has the added benefit of fewer days of bleeding/spotting compared to conventional and Fixed Extended regimens.

Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone

The effects of these COCs containing the newer progestogens dienogest and drospirenone with their antiandrogenic and antimineralocorticoid health benefits play an important role in the management of many diseases and their use should therefore be considered by clinician’s.

Antiandrogenic and Antimineralocorticoid Health Benefits of Combined Oral Contraceptives (= COC) containing Newer Progestogens: Dienogest and Drospirenone

This review will focus on the effects of COCs containing the newer progestogens dienogest and drospirenone with their antiandrogenic and antimineralocorticoid health benefits on the endometrium, the skin, the fat tissue and the premenstrual syndrome.

The use of newer progestins for contraception.

Beyaz®: An Oral Contraceptive Fortified with Folate

The folate-containing pill may aid in reducing the risk of neural tube defects in a pregnancy conceived during use or shortly after the discontinuation of the product.

A Comparative Efficacy of Low-Dose Combined Oral Contraceptives Containing Desogestrel and Drospirenone in Premenstrual Symptoms

In conclusion, low-dose COC containing either DSG or DRSP reduced premenstrual symptoms, but the latter showed greater efficacy and earlier reduction.

Low-Dose Acetazolamide in the Treatment of Premenstrual Dysphoric Disorder: A Case Series

It is suggested that acetazolamide may be used to improve symptoms of PMDD in cases not responding to other treatments, and GABAergic mechanisms may be involved in counteracting PMDD symptoms.

Targets to treat androgen excess in polycystic ovary syndrome

The authors review the potential targets and new drugs to treat androgen excess in PCOS, a common androgen disorder in reproductive-aged women who suffer from cardiometabolic risk even without treatment.

Does the presence of coexisting diseases modulate the effectiveness of a low-dose estrogen/progestin, ethinylestradiol/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women

Time-dependent changes in visual analog score for dysmenorrhea and alleviation of symptoms, such as lower abdominal pain, low back pain, headache, and nausea/vomiting, were similar in all patient groups with and without any specific coexisting organic diseases.

Adolescent female acne: etiology and management.



Drospirenone: pharmacology and pharmacokinetics of a unique progestogen.

Added benefits of drospirenone for compliance

  • J. Foidart
  • Medicine, Biology
    Climacteric : the journal of the International Menopause Society
  • 2005
Significant improvements were observed in quality of life during treatment with 1 mg 17β-estradiol/2 mg drospirenone, which also resulted in higher mean scores than estradiol alone, and that the effect on body weight is dependent on the dose of drospirnone, and this is due to droSpirenone's antimineralocorticoid activity.

Drospirenone: a Novel Progestogen with Antimineralocorticoid and Antiandrogenic Activity

Drospirenone exerts potent progestogenic and antigonadotropic activity which was studied in various animal species and efficiently promotes the maintenance of pregnancy in ovariectomized rats, inhibits ovulation in rats and mice and stimulates endometrial transformation in the rabbit.

Drospirenone in combination with estrogens: for contraception and hormone replacement therapy

  • W. Oelkers
  • Medicine, Biology
    Climacteric : the journal of the International Menopause Society
  • 2005
Drospirenone is not only a safe option for women using oral contraceptives or HRT, but it may offer new medical benefits, via its antimineralocorticoid and antialdosterone effects and its potential to decrease water retention and blood pressure.

Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms

  • D. ApterA. Borsos S. Kelly
  • Medicine
    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2003
3 mg drospirenone in combination with 30 μg ethinylestradiol has been shown to have a beneficial effect on psychological general well-being, as measured by thePGWBI, the first study on oral contraceptives which has used the PGWBI in this population.

Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties.

  • A. Rübig
  • Biology, Medicine
    Climacteric : the journal of the International Menopause Society
  • 2003
Phase III studies with E2/DRSP show that DRSP does not antagonize the well-documented reductions of blood pressure associated with E1; rather, small DRSP dose-related reductions in systolic and diastolic blood pressures were observed, which should be beneficial for recipients, especially those who are mildly hypertensive.

A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms.

An oral contraceptive containing drospirenone/ethinyl estradiol may reduce the premenstrual symptoms of negative affect, water retention and increased appetite.